GINWA(SH:600080)2014-10-24 16:00Financial Performance - Operating revenue for the first nine months rose by 48.67% to CNY 483,578,986.21 compared to the same period last year[8] - Net profit attributable to shareholders decreased by 5.60% to CNY 29,248,619.05 for the first nine months[8] - Basic earnings per share decreased by 5.62% to CNY 0.0958[9] - The weighted average return on equity decreased by 0.4341 percentage points to 2.8918%[8] - Total operating revenue for Q3 2014 reached ¥210,815,141.86, a significant increase from ¥116,901,549.17 in the same period last year, representing an increase of approximately 80%[33] - Net profit for the first nine months of 2014 was ¥28,168,502.63, compared to ¥32,322,934.67 in the same period last year, reflecting a decrease of approximately 13%[34] - The net profit attributable to the parent company for Q3 2014 was CNY 10,862,754.01, down 18.8% from CNY 13,375,552.28 in Q3 2013[35] - The total comprehensive income for Q3 2014 was CNY 10,234,296.12, down 23.8% from CNY 13,388,206.16 in the same quarter last year[35] Assets and Liabilities - Total assets increased by 5.54% to CNY 1,250,672,513.09 compared to the end of the previous year[8] - Total liabilities as of September 30, 2014, were ¥147,877,038.33, compared to ¥139,506,867.73 at the beginning of the year, marking an increase of approximately 6.5%[30] - The company's total equity reached ¥1,034,737,023.44 as of September 30, 2014, up from ¥998,643,128.81 at the start of the year, indicating a growth of about 3.6%[30] Cash Flow - The company reported a net cash flow from operating activities of CNY 16,966,487.61, a decrease of 2.31% compared to the previous year[8] - The cash flow from operating activities for the first nine months of 2014 was CNY 433,559,909.12, an increase of 26.3% from CNY 343,340,663.48 in the same period last year[40] - The net cash flow from operating activities for Q3 2014 was CNY 16,966,487.61, slightly down from CNY 17,368,198.61 in Q3 2013[41] - Cash and cash equivalents increased by 6,325,025.20 CNY, a growth of 39.78%, mainly due to the maturity of financial products[14] - Cash and cash equivalents at the end of the period increased to $103.50 million, up from $54.41 million year-on-year[46] Receivables and Payables - Accounts receivable rose by 70,101,370.61 CNY, a significant increase of 75.35%, attributed to higher sales revenue and changes in sales models[14] - Accounts payable surged by 38,554,554.38 CNY, marking a 100.73% increase, mainly due to higher procurement amounts in the pharmaceutical sector[14] - Other receivables increased by 5,074,333.43 CNY, a growth of 61.61%, mainly due to increased operational receivables at the end of the reporting period[14] - The company reported a significant increase in other receivables, which rose to ¥11,407,271.89 from ¥4,238,112.00, indicating a growth of about 169%[29] Expenses - Operating costs increased by 102,992,104.06 CNY, a rise of 80.92%, primarily due to increased sales volume and operational costs[17] - Sales expenses increased by 58,482,704.90 CNY, a rise of 48.72%, driven by increased sales volume and promotional efforts[17] - The company incurred sales expenses of CNY 66,460,116.52 in Q3 2014, which is a 50.5% increase compared to CNY 44,136,700.61 in Q3 2013[37] Shareholder Information - The total number of shareholders reached 33,025 by the end of the reporting period[10] - The largest shareholder, Jinhua Investment Holdings Group Co., Ltd., holds 25.55% of the shares, with 43,450,000 shares pledged[10] Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in this report[8]